Latest Paclitaxel Stories
MAJESTIC Trial Meets Performance Endpoint With Compelling Results MARLBOROUGH, Mass., April 28, 2015 /PRNewswire/ -- In an important clinical advancement in the treatment of peripheral artery
CYRAMZA Now Approved in the U.S.
-- Cantrixil receives Orphan Drug Designation in U.S.
Updated clinical data presented in an oral session at the 2015 American Association for Cancer Research Annual Meeting CAMBRIDGE, Mass., April 21, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals,
UPPSALA, Sweden, April 20, 2015 /PRNewswire/ -- Oasmia Pharmaceutical AB ("Oasmia") announced today that its lead cancer product Paclical received market authorization
-- Animal model highly representative of late-stage ovarian cancer in women PHILADEPHIA, April 20, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Ltd, (ASX:NRT;
Data to support ongoing work with Halozyme's investigational new drug PEGPH20 in combination with immuno-oncology agents SAN DIEGO, April 20, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc.
SAN DIEGO, April 18, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc.
Recent FDA meeting allows for potential marketing application based on progression free survival in pivotal Phase 3 pancreatic cancer study SAN DIEGO, April 8, 2015 /PRNewswire/ -- Halozyme
LONDON, April 8, 2015 /PRNewswire/ -- SummaryGBI Research, has released the pharma report -"Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline
- A serpent whose bite was fabled to produce intense thirst.